What Klion-D treats: Main Uses and Benefits

Klion-D is used to help manage local urogenital infections that are caused by susceptible mixed pathogens. The treatment is used in the management of the underlying cause and associated symptomatic distress. This involves the use of co-formulated metronidazole and miconazole for these indications.

---

Key Therapeutic Focus

This medication is commonly used to help manage conditions such as Trichomoniasis, Bacterial Vaginosis (BV), and Vaginal Candidiasis (yeast infections) when they may occur together. The combination approach is applied in situations where symptoms suggest the co-existence of multiple susceptible pathogens simultaneously.

The treatment is relevant in contexts marked by increased discomfort and tension, helping address symptom clusters that include pronounced vaginal itching (pruritus), a burning sensation, and local irritation. It may also assist with promoting comfort by helping to ease discomfort experienced during sexual activity (dyspareunia) and managing abnormal vaginal discharge. The medication may support the patient during difficult episodes by easing distress and may contribute to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Localized Inflammatory Discomfort

Regulatory References

1. National Institute of Allergy and Infectious Diseases (NIAID) Study on Metronidazole and Miconazole Suppositories

Who Can and Cannot Use Klion-D?

This section outlines the official population eligibility and non-eligibility rules for Klion-D (Metronidazole + Miconazole Nitrate vaginal tablets), based strictly on governmental regulatory documents.

---

Contraindicated Populations and Restrictions

Classification	Rule
Absolute Contraindication	Patients with known hypersensitivity to Metronidazole, Miconazole, or any component.
	Patients with Acute Porphyria.
	Use during the First Trimester of Pregnancy is contraindicated.
Conditional/Restricted Use	Use is not recommended for children under 12 years of age.
	Patients with severe hepatic impairment or hepatic encephalopathy require caution and possible dose modification.
Substance Exclusion	Alcohol consumption is contraindicated during therapy and for 24–72 hours after the last dose.
	Concurrent or recent use of Disulfiram (within two weeks) is contraindicated.

---

Eligibility Status

Use is generally established for Adult Females and Adolescent Females aged 12 years and older. Use during lactation (breastfeeding) is restricted; interruption of breastfeeding is advised during treatment and for 24–48 hours after the last dose. Use during the Second and Third Trimester of Pregnancy requires conditional use only when deemed essential by a physician.

Interactions with other medicines and products

Official government regulatory sources document several significant interaction patterns for the active ingredients Metronidazole and Miconazole Nitrate, which define mandatory restrictions and monitoring requirements.

Contraindicated Combinations and Timing Rules

Substance	Interaction Classification	Official Restriction
Alcohol and Propylene Glycol	Disulfiram-like reaction (pharmacodynamic)	Consumption must be avoided during therapy and for at least 72 hours (3 days) after the final dose.
Disulfiram	Psychotic reactions (additive CNS effects)	Contraindicated; administration must be separated by at least 14 days.
Latex Products	Physical interaction	Do not use concurrently with latex-based barrier contraceptives (e.g., condoms, diaphragms), as the excipients may compromise their integrity.

---

Exposure-Modifying and Pharmacokinetic Interactions

Co-administration with several medicines is documented to alter their plasma concentrations, requiring specialized monitoring:

• Oral Coumarin Anticoagulants (e.g., Warfarin): Both Metronidazole and Miconazole are documented to potentiate the anticoagulant effect, requiring careful, mandatory monitoring of Prothrombin time/INR due to increased bleeding risk.
• Lithium: Metronidazole is noted to increase serum lithium concentrations, which necessitates measuring serum lithium levels during co-administration.
• Phenytoin and Busulfan: Metronidazole may increase the plasma levels of both Phenytoin and Busulfan, thereby increasing the risk of toxicity for the co-administered drug.
• Cimetidine: This drug is reported to reduce the clearance of Metronidazole, potentially leading to increased Metronidazole exposure.

Population-Specific Notes: The potential for Metronidazole accumulation and increased interaction risk is noted in patients with severe hepatic impairment due to reduced clearance and in end-stage renal disease patients due to metabolite accumulation.

Dual-Mechanism Pathogen Destruction

The action of this agent is characterized by two distinct, non-overlapping mechanisms that target different classes of organisms. This dual action involves simultaneous interference with separate survival pathways, resulting in the destruction of susceptible cells.

---

Targeting Genetic Material (Metronidazole Action)

The metronidazole component is activated only inside susceptible anaerobic protozoa and bacteria via enzymatic reduction. This process generates highly reactive cytotoxic nitro radicals that damage and fragment the organisms' DNA. This molecular action immediately inhibits the synthesis of nucleic acids and blocks cell replication, leading to cell death and the subsequent destruction of these susceptible organisms.

---

Blocking Fungal Cell Membrane Synthesis (Miconazole Action)

The miconazole component functions as an inhibitor of the fungal enzyme lanosterol 14-alpha demethylase. This enzyme is crucial for the synthesis of ergosterol, the primary sterol responsible for maintaining fungal cell membrane integrity. Inhibition of this pathway causes ergosterol depletion and results in a structurally compromised, leaky cell membrane, ultimately leading to cell destabilization and the diminishing of the population of susceptible fungal cells.

The medicine, a combination of Metronidazole and Miconazole Nitrate, is intended for intravaginal use as a tablet or ovule. The standard regimen involves the insertion of one vaginal tablet once daily, typically performed in the evening before rest. For certain conditions, the regimen is a dual-modality protocol requiring concurrent systemic treatment with oral Metronidazole, which is often split into two daily doses and must be taken during or after meals.

Proper application requires specific preparation: the vaginal tablet should be slightly moistened with water immediately prior to insertion and placed high up into the vagina while the patient is in a lying position. The standard course duration generally lasts between seven and fourteen days, depending on whether the case is recurrent. The use of the vaginal product is strictly restricted to the intravaginal route and must not be swallowed. The standard adult dose generally applies to older adults (aged 65 and over), but the medicine is not for use in children under 12 years of age. A missed dose is generally omitted if it is almost time for the next dose, and the regular schedule is then resumed.

Research Evidence / Overview of Studies for Klion-D

The research evidence explores the metronidazole and miconazole combination vaginal tablet in studies of Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis [1.1, 1.6]. The findings below summarize the scope of the clinical evaluation based on studies available in scientific and regulatory literature, describing what was examined and what is still uncertain.

---

Evidence for Use in Mixed Vaginal Infections

Clinical studies focused on mixed vaginal infections, which are conditions involving the presence of both protozoa/bacteria and fungi simultaneously. Research has utilized open-label and comparative trials to study the regimen for these co-existing pathogens. Studies described initial, short-term findings in measurements taken for both sets of microorganisms, particularly when evaluated shortly after the study interval concluded [1.6].

Evidence for Use in Bacterial Vaginosis (BV)

The metronidazole and miconazole vaginal tablet was observed in research for Bacterial Vaginosis (BV), including Randomized Controlled Trials (RCTs). Short-term results of these trials reported patterns observed in symptom scores and microbiological changes [1.1, 1.7]. In some comparative research, findings describe patterns where short-term outcomes measured were observed alongside those measured for oral metronidazole [1.1, 1.7].

---

Overview of Long-Term Evidence and Recurrence

Studies have monitored patient outcomes over defined time intervals, from short-term assessment to intermediate (around 1–3 months) and sometimes up to 12 months for monitoring recurrence [1.4, 2.7]. The research describes patterns where long-term outcomes, particularly for Bacterial Vaginosis, may be variable across various treatment types. Therefore, the sustained durability of the effect and long-term cure rates are not fully established and remain areas where more research is needed [2.7].

Key Areas of Research Uncertainty

Research data for populations with certain comorbid conditions (e.g., severe liver or nervous system disorders) are limited as these groups were generally not included in the main trials [3.1]. Also, local vaginal treatment research for Trichomoniasis does not examine outcomes related to the management of sexual partners. The evidence quality varies across studies, with many earlier studies being open-label or non-comparative [1.6].

Common questions about Klion-D (FAQ)

---

Q: Is Klion-D an antibiotic, or does it belong to another type of medicine?

The Klion-D product is officially classified as an anti-infective combination product. The Metronidazole component within Klion-D is an antibiotic that belongs to the nitroimidazole class. This part of the medication is designed to target certain susceptible protozoa and bacteria.

---

Q: Why is Klion-D often used for fungal or yeast issues?

The reason the product is used for these issues is that it contains Miconazole Nitrate. According to the official product information, Miconazole Nitrate is an antifungal agent. This component is specifically designed to treat infections caused by susceptible fungi, which are commonly known as yeast issues.

---

Q: Why do official sources sometimes mention liver concerns with one of the components?

Official documents advise that caution is necessary for patients who have severe hepatic, or liver, impairment. This warning is primarily due to the Metronidazole component, as there is a documented risk of drug accumulation in the body. For this reason, official labeling describes the need for careful monitoring or possible dose alteration in these cases.

---

Q: Is there any research on using Klion-D during the early stages of pregnancy?

Official documents state that the use of Klion-D is contraindicated (not allowed) during the first trimester of pregnancy. While research has examined the use of the single-agent Metronidazole component during pregnancy, controlled human data for the specific combination product may be limited or is not generally established.

---

Q: Can Klion-D be used while breastfeeding?

Official guidelines state that breastfeeding should be interrupted while a person is undergoing treatment with Klion-D. This interruption is necessary because the active ingredients pass into breast milk. Regulatory advice suggests that breastfeeding should be paused for a period of 24 to 48 hours following the final dose of the medication.

---

Q: Does Klion-D affect the effectiveness of hormonal birth control?

Regulatory documents note a physical interaction with latex barrier contraceptives. For the low systemic absorption associated with this vaginally administered product, official sources often indicate that an interaction with oral hormonal birth control is generally not expected. However, documentation may be inconsistent.

---

Q: How long after finishing Klion-D can I resume sexual activity according to guidelines?

Official guidance for certain conditions treated with metronidazole-based agents has included advisories to avoid sexual intercourse for a defined period, such as for 7 days, following completion of treatment. This guidance is usually related to preventing re-infection.

---

Q: What is the difference between this combination product and single-agent Metronidazole?

The key difference is that Klion-D provides a dual action formula. Single-agent Metronidazole only targets susceptible protozoa and bacteria. The Klion-D combination adds Miconazole Nitrate to also target susceptible fungi, offering a broader spectrum of localized anti-infective activity.

---

Q: Do both components of Klion-D treat the same thing?

No, the two active components do not treat the same thing; they target different types of organisms. Metronidazole targets susceptible protozoa and bacteria, and Miconazole Nitrate targets susceptible fungi. The combination is formulated to treat mixed infections involving both classes of pathogens simultaneously.

---

Q: Are there any specific foods or drinks that should be avoided while using Klion-D?

Official documents describe that the avoidance of alcohol (and propylene glycol) is required during treatment and for a specified time afterward to prevent a potential severe reaction. Beyond these substances, regulatory documents typically do not list specific foods or non-alcoholic drinks that must be avoided while using this medication.

---

Q: Is Klion-D available in forms other than vaginal tablets or suppositories?

Klion-D is specifically formulated and manufactured as a vaginal tablet or pessary. This is the official pharmaceutical form designed for local administration, which delivers the dual active ingredients where they are required for treatment.

---

Q: Can men use Klion-D for treatment?

The official eligibility status for Klion-D, which is a vaginal tablet, is generally established for Adult Females and Adolescent Females (aged 12 and older). This definition is based on the drug's approved vaginal route of administration.

---

Q: What should be done if an accidental oral ingestion of Klion-D occurs?

Official instructions emphasize that the product is strictly for intravaginal use only. In cases of accidental oral ingestion, the management is guided by the potential systemic effects of the Metronidazole component. Specific guidance for suspected overdose is outlined in official medical protocols.

---

Q: Do official documents mention any potential long-term effects of using Klion-D?

Official regulatory documents for the Metronidazole component contain information regarding findings in non-clinical studies. This includes findings in animal studies concerning carcinogenicity (cancer risk) after high-dose, long-term oral exposure, which is noted in the product labeling as a required safety constraint.

---

Q: What is the risk of resistance developing to Klion-D?

The official information for the product is based on its activity against susceptible organisms. As is described for all anti-infective medicines, clinical and research literature discusses the potential for targeted organisms to develop reduced susceptibility, or resistance, to the drug over time.

---

Q: Can Klion-D be used during menstruation?

Official guidelines and patient information leaflets generally describe that treatment with Klion-D may be continued even if menstruation occurs. This approach is generally followed to ensure that the full course of medication is completed as prescribed.

---

Q: Does Klion-D interact with any common over-the-counter pain relievers?

Official regulatory documents generally focus on systemic interactions. They typically do not report known interactions between the vaginally-administered components of Klion-D and common over-the-counter pain relievers, such as Paracetamol or Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

---

Q: Is Klion-D used to treat bacterial vaginosis?

The Klion-D combination product is indicated for the local treatment of mixed vaginal infections. Its Metronidazole component is a recognized and established agent used in the clinical treatment of Bacterial Vaginosis (BV).

---

Q: Why is it important to complete the full course of Klion-D, even if symptoms improve?

Official patient information states that completing the full course is described as important for therapeutic stability. Discontinuing the medicine early, even if symptoms improve or disappear, carries the risk that the infection may still be present and could recur.

How to Store and Dispose of Klion-D?

Klion-D vaginal tablets must be stored according to regulatory requirements to ensure product stability. The medication requires storage at controlled room temperature, specifically between 15 C and 30 C (59 F to 86 F), and must not exceed the upper limit. It is necessary to keep the product in its original, tightly closed container and protect it from moisture. To prevent accidental exposure, the medicine must always be stored securely, out of the reach and sight of children.

Disposal of expired or unused Klion-D must follow official guidelines. The product should be discarded after its expiration date. The preferred method for disposal of most unused medicines is to use a drug take-back program. When such programs are unavailable, disposal into household trash must be done by mixing the medicine with an undesirable substance and placing it in a sealed container.